Marken adding nursing network for at-home clinical trials

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Halfpoint)
(Image: Getty/Halfpoint)
Marken is planning to develop a global home-based nursing network as an increasing amount of clinical trial protocols now include a DTP/DFP component.

Marken currently offers its Direct to/from Patient (DTP/DFP) services in 51 countries. The new nursing services will enable the company to collect a patient’s biological samples in their home and in accordance with clinical protocols.

Services will potentially include intravenous infusion, blood draws including safety lab samples, biologic sampling, such as pharyngeal and oral mucosal swabs, in addition to clinical assessment of vital signs and other mobile-based electronic data collection, according to the company.

Additionally, nurses and patients in the US are able to drop off biological samples at any one of 4,600 The UPS Store locations​.

The number of nurses contracted to work with Marken will depend on patient locations, protocol design, number of patients, and the countries in which the trial will take place, explained Christine Noble, senior director, global marketing, Marken.

“We expect that the Marken nursing network will grow rapidly and exponentially in response to the increasing number of trial protocols which are already including DTP/DFP for patients,”​ Noble added. “This new service will offer more options for patients and sponsors.”

The network will be available to countries where regulators permit DTP and DFP services for patients enrolled in clinical trials, Noble explained, and for a trial in which sponsors have added a DTP/DPF component to the trial protocol.

“Many times, the indication for the trial can drive the need for a DTP/DFP component,”​ she added

Marken continues to experience growth across Asia, Noble said, and more trials are underway in Russia, Ukraine, Israel, and several other countries in the Middle East.

“As more and more countries recognize the need, we expect that the number of countries in which the service can be offered will continue to increase,” ​she added.

Wes Wheeler, Marken CEO, noted in the release that “24% of pharmaceutical companies are moving to virtual or partially virtual trials and another 33% are expected to start ‘siteless’ trials in the near future.” 

“We expect this trend will continue to place a heavy demand for our services,” ​he said.

Related news

Show more

Related products

show more

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us


View more